HIF-1–mediated PPME1 expression promotes breast cancer progression via AKT activation and β-catenin recruitment
Journal of Clinical Investigation · 2026
DOI: 10.1172/jci205415 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Yajing Lyu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Cell Engineering and. Hauptthemen laut MEDLINE: Breast Neoplasms, beta Catenin, Proto-Oncogene Proteins c-akt, Gene Expression Regulation, Neoplastic. Die Arbeit nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Armstrong Family Foundation.
Abstract (Originalsprache)
Hypoxia-inducible factor 1 (HIF-1) orchestrates the transcriptional regulation of thousands of genes involved in breast cancer (BC) progression. Here, we identified protein phosphatase 2A (PP2A) methylesterase 1 ( PPME1 ) as a critical HIF-1 target gene that drives oncogenic signaling under hypoxic conditions. In BC cells, HIF-1–dependent PPME1 expression caused inhibition of the PP2A catalytic subunit (PP2Ac), thereby diminishing PP2A activity, which led to AKT activation, phosphorylation of β-catenin, and its nuclear translocation. Nuclear β-catenin cooperates with HIF-1 to promote BC stem cell specification by activating transcription of the NANOG and KLF4 genes, which encode pluripotency factors, and to drive immune evasion by activating transcription of VEGFA , which recruits and polarizes immunosuppressive tumor-associated macrophages and ISG20 , which represses STAT1/IRF1-dependent expression of CXCL10 , thereby impairing CD8 + T cell recruitment. In vivo, PPME1 knockdown altered the tumor immune microenvironment, enhanced antitumor immunity, and synergized with anti–CTLA-4 immunotherapy to enable complete tumor eradication. These findings establish PPME1 as a critical regulator linking hypoxia signaling, stemness, and immune evasion and highlight its potential as a BC therapeutic target in combination with immune checkpoint blockade.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Cell Engineering and.
- Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Johns Hopkins University, Baltimore, Maryland, USA.
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA.
Förderung
- Armstrong Family Foundation
Zitieren
APA
Lyu, Y., Talwar, V., Yang, Y., Kang, S. S., Li, S., Salman, S., Drehmer, D., Wang, Y., Chen, C., Ramu, V., Kim, S., Park, D., Huang, T. Y., Datan, E., Dordai, D., Schneck, J. P., & Semenza, G. L. (2026). HIF-1–mediated PPME1 expression promotes breast cancer progression via AKT activation and β-catenin recruitment. Journal of Clinical Investigation. https://doi.org/10.1172/jci205415
Vancouver
Lyu Y, Talwar V, Yang Y, Kang SS, Li S, Salman S, et al. HIF-1–mediated PPME1 expression promotes breast cancer progression via AKT activation and β-catenin recruitment. Journal of Clinical Investigation. 2026. doi:10.1172/jci205415
BibTeX
@article{Lyu2026,
author = {Lyu, Yajing and Talwar, Varen and Yang, Yongkang and Kang, Si-Sim and Li, Shuyi and Salman, Shaima and Drehmer, Daiana and Wang, Yufeng and Chen, Chelsey and Ramu, Vijay and Kim, Sujin and Park, Dylan and Huang, Tina Yi-Ting and Datan, Emmanuel and Dordai, Dominic and Schneck, Jonathan P and Semenza, Gregg L},
title = {HIF-1–mediated PPME1 expression promotes breast cancer progression via AKT activation and β-catenin recruitment},
journal = {Journal of Clinical Investigation},
year = {2026},
doi = {10.1172/jci205415}
}
EUVIMED